Moderna will be expanding its Moderna Technology Center (MTC) in Norwood, Massachusetts including more than doubling of space to transform the facility from a production and lab space to an industrial technology center.
This expansion includes increasing the company’s production and lab space from approximately 300,000 square feet to approximately 650,000 square feet through renovation of existing space and acquisition of a 240,000 square foot building located on the same campus.
Moderna says this investment and expansion will allow it to continue to optimize mRNA products as it explores new pharmaceutical delivery forms such as prefilled syringes and lyophilized products.
This expansion will support a 50% increase in production of the Moderna COVID-19 Vaccine at its manufacturing site, which is expected to ramp up in late 2021 and early 2022. Moderna recently revealed an investment at its owned and partnered manufacturing facilities that it expects will increase 2022 global capacity to up to 3 billion doses of its COVID-19 vaccine, depending upon the mix between the authorized Moderna COVID-19 vaccine at the 100 μg dose level and potentially lower doses of the company’s variant booster candidates and pediatric vaccines, if authorized. The company also raised its 2021 manufacturing supply forecast to between 800 million to 1 billion doses.
This expansion includes an increase in Moderna’s technical development capacity and preclinical production capability with the goal of producing thousands of preclinical samples per month for research and development. The expanded facility will also help facilitate the company’s focus and investment in the expansion of shelf-life stability and new pharmaceutical delivery forms such as prefilled syringes and lyophilized products.
Moderna opened its manufacturing site in July 2018.
Read the Moderna statement